Advertisement

Research Article Free access | 10.1172/JCI118088

Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.

S Scala, A Budillon, Z Zhan, Y S Cho-Chung, J Jefferson, M Tsokos, and S E Bates

Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

Find articles by Scala, S. in: JCI | PubMed | Google Scholar

Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

Find articles by Budillon, A. in: JCI | PubMed | Google Scholar

Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

Find articles by Zhan, Z. in: JCI | PubMed | Google Scholar

Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

Find articles by Cho-Chung, Y. in: JCI | PubMed | Google Scholar

Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

Find articles by Jefferson, J. in: JCI | PubMed | Google Scholar

Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

Find articles by Tsokos, M. in: JCI | PubMed | Google Scholar

Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

Find articles by Bates, S. in: JCI | PubMed | Google Scholar

Published August 1, 1995 - More info

Published in Volume 96, Issue 2 on August 1, 1995
J Clin Invest. 1995;96(2):1026–1034. https://doi.org/10.1172/JCI118088.
© 1995 The American Society for Clinical Investigation
Published August 1, 1995 - Version history
View PDF
Abstract

8-Cl-cAMP, a site-selective analogue of cAMP, decreased mdr-1 expression in multidrug-resistant human breast cancer cells. A sixfold reduction of mdr-1 mRNA expression by 8-Cl-cAMP began within 8 h of treatment and was associated with a decrease in the synthesis of P-glycoprotein and with an increase in vinblastine accumulation. A reduction in mdr-1 expression after 8-Cl-cAMP treatment was also observed in multidrug-resistant human ovarian cancer cell lines. 8-Cl-cAMP is known to change the ratio between the two regulatory subunits, RI and RII, of protein kinase A (PKA). We observed that RI alpha decreased within 24 h of 8-Cl-cAMP treatment, that RII beta increased after as few as 3 h of treatment, and that PKA catalytic activity remained unchanged during 48 h of 8-Cl-cAMP treatment. The results are consistent with the hypothesis that mdr-1 expression is regulated in part by changes in PKA isoenzyme levels. Although 8-Cl-cAMP has been used to differentiate cells in other model systems, the only differentiating effect that could be detected after 8-Cl-cAMP treatment in the MCF-7TH cells was an increase in cytokeratin expression. Evidence that the reduction of mdr-1 mRNA occurred at the level of gene transcription was obtained by measuring chloramphenicol acetyltransferase (CAT) mRNA in MCF-7TH cells transfected with an mdr-1 promoter-CAT construct prior to 8-Cl-cAMP treatment. Thus, 8-Cl-cAMP is able to downregulate mdr-1 expression and suggests a new approach to reversal of drug resistance in human breast cancer.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (August 1, 1995): No description
Advertisement
Advertisement